Jazz Pharmaceuticals

Jazz Pharmaceuticals is a global biopharmaceutical company dedicated to bringing life-changing medicines to people with limited or no options. Headquartered in Dublin, Ireland, the company has a significant presence in the United States, Europe, and other international markets, with offices in locations including Palo Alto, Carlsbad, Philadelphia, Vancouver, Mississauga, London, Oxford, Cambridge, Lyon, Munich, Madrid, Roscommon, and Villa Guardia. Jazz Pharmaceuticals focuses on two main therapeutic areas: neuroscience and oncology, and has a diverse portfolio of marketed medicines, including leading therapies for sleep disorders, epilepsy, and a growing portfolio of cancer treatments. Their product portfolio includes Epidiolex, Xyrem, Xywav, Defitelio, Rylaze, Vyxeos, and Zepzelca. The company is actively involved in clinical trials and research to develop new therapies for various conditions, including cancer and neurological disorders. Notable investigational products include Zanidatamab, a HER2-targeted bispecific antibody, and Lurbinectedin, approved for small cell lung cancer. Jazz Pharmaceuticals has received multiple Fast Track and Orphan Drug designations from the U.S. FDA and the European Medicines Agency for their investigational products. The company is committed to corporate sustainability, social impact, ethical standards, and corporate giving. Jazz Pharmaceuticals emphasizes patient-centric innovation and has been involved in several strategic collaborations and acquisitions to expand their product offerings and capabilities.